
|Videos|September 10, 2019
Dr. Tolba on Targeting NRG1 Fusions in NSCLC
Author(s)Khaled A. Tolba MD, MBBCh
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non-small cell lung cancer.
Advertisement
Khaled A. Tolba MD, MBBCh, assistant professor of medicine, School of Medicine, Oregon Health & Science University, provides data from a study on targeting NRG1 fusions in non—small cell lung cancer (NSCLC).
Recently presented during the 2019 World Conference on Lung Cancer, Tolba’s research shows that afatinib (Gilotrif) has activity in NRG1-fusion positive NSCLC. This adds to other research, however, a study with a larger cohort is suggested for the future.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































